Pharmacology
9 questionsWhich of the following oral antidiabetic drugs is an insulin secretagogue?
Which of the following is a PGE1 analogue used in medical treatments?
Which of the following is a long-acting beta-2 agonist?
Which triptan is available in nasal spray form?
Acetaminophen [Paracetamol] induced liver toxicity is due to which metabolite?
Which of the following drugs is commonly used as a rescue medication for acute asthma attacks?
Which of the following statements best describes the underlying mechanism of heparin-induced thrombocytopenia?
Which of the following statements about oral iron preparations is correct?
What is the mechanism of action of ticagrelor?
NEET-PG 2015 - Pharmacology NEET-PG Practice Questions and MCQs
Question 511: Which of the following oral antidiabetic drugs is an insulin secretagogue?
- A. Metformin
- B. Pioglitazone
- C. Nateglinide (Correct Answer)
- D. Acarbose
Explanation: **Nateglinide** - **Nateglinide** is a **meglitinide**, which is a type of **insulin secretagogue**. - It stimulates **insulin release** from pancreatic beta cells by blocking ATP-sensitive potassium channels. *Metformin* - **Metformin** is a **biguanide** that primarily works by **decreasing hepatic glucose production** and increasing insulin sensitivity in peripheral tissues. - It does not directly stimulate insulin secretion. *Pioglitazone* - **Pioglitazone** is a **thiazolidinedione** (TZD) that improves insulin sensitivity by activating **PPAR-gamma receptors**. - It does not directly affect insulin secretion but rather enhances the body's response to existing insulin. *Acarbose* - **Acarbose** is an **alpha-glucosidase inhibitor** that delays the digestion and absorption of carbohydrates in the small intestine. - This reduces postprandial glucose excursions and does not directly stimulate insulin secretion.
Question 512: Which of the following is a PGE1 analogue used in medical treatments?
- A. Carboprost
- B. Alprostadil (Correct Answer)
- C. Epoprostenol
- D. Dinoprostone
Explanation: ***Alprostadil*** - **Alprostadil** is a synthetic **prostaglandin E1 (PGE1)** analogue. - It is used in neonates to maintain the **patency of the patent ductus arteriosus** and in adults for the treatment of **erectile dysfunction**. *Carboprost* - **Carboprost** is a synthetic analogue of **prostaglandin F2 alpha (PGF2α)**. - It is primarily used to manage **postpartum hemorrhage** due to its potent uterotonic effects. *Epoprostenol* - **Epoprostenol** is a synthetic analogue of **prostacyclin (PGI2)**. - It is known for its potent **vasodilatory** and **antiplatelet** properties, making it useful in treating **pulmonary arterial hypertension**. *Dinoprostone* - **Dinoprostone** is a synthetic form of **prostaglandin E2 (PGE2)**. - It is used to **induce labor** or **cervical ripening** due to its role in uterine contractions and cervical dilation.
Question 513: Which of the following is a long-acting beta-2 agonist?
- A. Isoprenaline
- B. Ephedrine
- C. Salbutamol
- D. Formoterol (Correct Answer)
Explanation: ***Formoterol*** - **Formoterol** is a **long-acting beta-2 agonist (LABA)** commonly used in the treatment of asthma and COPD. - It provides **bronchodilation** for up to 12 hours due to its high lipophilicity, allowing it to remain in the cell membrane and continuously activate beta-2 receptors. *Isoprenaline (non-selective adrenergic agonist)* - **Isoprenaline** is a **non-selective beta-adrenergic agonist**, meaning it activates both beta-1 and beta-2 receptors. - It is **short-acting** and primarily used as a vasodilator or to stimulate heart rate, not as a long-acting bronchodilator. *Ephedrine (non-selective adrenergic agonist)* - **Ephedrine** is a **mixed-acting sympathomimetic amine** that increases the release of norepinephrine and directly stimulates alpha and beta receptors. - It has a short duration of action and is primarily used as a decongestant or bronchodilator in emergency situations, not as a long-acting agent. *Salbutamol (short-acting beta-2 agonist)* - **Salbutamol** is a **short-acting beta-2 agonist (SABA)**, providing rapid onset but a short duration of action (typically 4-6 hours). - It is used for **relieving acute bronchospasm** and is not considered a long-acting medication for maintenance therapy.
Question 514: Which triptan is available in nasal spray form?
- A. Sumatriptan (Correct Answer)
- B. Rizatriptan
- C. Naratriptan
- D. Frovatriptan
Explanation: ***Sumatriptan*** - **Sumatriptan** is available in multiple formulations, including **oral, subcutaneous injection, and nasal spray**, making it versatile for migraine treatment [1], [2]. - The nasal spray formulation allows for **faster absorption** and onset of action, which can be beneficial for patients with nausea or vomiting during migraine attacks [1]. *Rizatriptan* - **Rizatriptan** is primarily available in **oral tablet** and **orally disintegrating tablet** (ODT) forms [2]. - It does not have a commonly available nasal spray formulation for migraine treatment [2]. *Naratriptan* - **Naratriptan** is available as an **oral tablet** and is known for its **longer half-life** and generally milder side effect profile compared to sumatriptan [2]. - It is not available in a nasal spray formulation [2]. *Frovatriptan* - **Frovatriptan** is available exclusively as an **oral tablet** and is notable for having the **longest half-life** among triptans, making it useful for preventing recurring migraines [2]. - There is no nasal spray formulation for frovatriptan [2].
Question 515: Acetaminophen [Paracetamol] induced liver toxicity is due to which metabolite?
- A. Co-Q
- B. Cytochrome 'C'
- C. NAPQI (Correct Answer)
- D. N-acetylcysteine
Explanation: ***NAPQI*** - **N-acetyl-p-benzoquinone imine (NAPQI)** is a highly reactive and toxic metabolite produced during acetaminophen metabolism, especially in overdose situations [1, 3]. - When glutathione stores are depleted due to excessive NAPQI formation, this metabolite covalently binds to hepatic macromolecules, causing **hepatocellular damage and necrosis** [1, 3].*N-acetylcysteine* - **N-acetylcysteine (NAC)** is the antidote for acetaminophen overdose, not the toxic metabolite itself [2, 3]. - NAC works by replenishing hepatic **glutathione stores**, which helps detoxify NAPQI and prevent liver injury [2, 3].*Co-Q* - **Coenzyme Q10 (CoQ10)** is an endogenous antioxidant and electron carrier in the mitochondrial respiratory chain. - It is not a metabolite of acetaminophen and plays no direct role in acetaminophen-induced liver toxicity.*Cytochrome 'C'* - **Cytochrome c** is a protein involved in the electron transport chain in mitochondria and plays a critical role in apoptosis. - While cellular damage from NAPQI can eventually lead to cytochrome c release and apoptosis, cytochrome c itself is not a metabolite of acetaminophen or the direct cause of toxicity.
Question 516: Which of the following drugs is commonly used as a rescue medication for acute asthma attacks?
- A. Salbutamol (Correct Answer)
- B. Theophylline
- C. Terbutaline
- D. Budesonide
Explanation: ***Salbutamol*** - **Salbutamol** (albuterol) is a **short-acting beta-2 agonist (SABA)** that rapidly relaxes bronchial smooth muscle. - Its quick onset of action makes it ideal for immediate relief of **bronchoconstriction** during an acute asthma attack. - It is the **most commonly used** and **first-line rescue medication** for acute asthma worldwide. *Terbutaline* - **Terbutaline** is also a **short-acting beta-2 agonist (SABA)** similar to salbutamol and can be used as a rescue medication. - While it has comparable bronchodilator effects, **salbutamol is more commonly used** as the preferred rescue inhaler in clinical practice. - Both are SABAs, but salbutamol has become the standard first-choice rescue medication globally. *Theophylline* - **Theophylline** is a **methylxanthine** that acts as a bronchodilator but has a **narrow therapeutic index** and slower onset of action. - It is used as a **maintenance therapy** for chronic asthma and not as a rescue drug for acute exacerbations. *Budesonide* - **Budesonide** is an **inhaled corticosteroid (ICS)** used as a **long-term controller medication** to reduce airway inflammation. - It has a slow onset of action and is *not* effective for immediate relief during an acute asthma attack.
Question 517: Which of the following statements best describes the underlying mechanism of heparin-induced thrombocytopenia?
- A. Low molecular weight heparin can also cause heparin-induced thrombocytopenia.
- B. Vitamin K is not an antidote for heparin-induced thrombocytopenia.
- C. Heparin-induced thrombocytopenia can occur after several days of heparin therapy.
- D. Antibodies are formed against heparin-platelet factor 4 complexes. (Correct Answer)
Explanation: **_Antibodies are formed against platelet factor 4._** - The underlying mechanism of **heparin-induced thrombocytopenia (HIT)** involves the formation of antibodies against complexes of **heparin and platelet factor 4 (PF4)** [2]. - These antibodies bind to the **heparin-PF4 complexes** on the surface of platelets, leading to platelet activation, aggregation, and consumption, which results in thrombocytopenia and a prothrombotic state [2]. *Low molecular weight heparin can also cause heparin-induced thrombocytopenia.* - While **low molecular weight heparin (LMWH)** has a lower incidence of causing HIT compared to unfractionated heparin, it can still trigger the condition [1], [2]. - This is because LMWH, like unfractionated heparin, can form complexes with PF4, leading to the same immune response in susceptible individuals [2]. *Vitamin K is not an antidote for heparin-induced thrombocytopenia.* - **Vitamin K** is the antidote for warfarin overdose, which works by reversing its anticoagulant effects [3]. - It has no role as an antidote for HIT because HIT is an **immune-mediated reaction** involving platelet activation, not a direct anticoagulant effect that can be reversed by Vitamin K [2]. *Heparin-induced thrombocytopenia can occur after several days of heparin therapy.* - HIT typically manifests after **5 to 10 days of heparin exposure**, as it takes time for the immune system to produce antibodies against the heparin-PF4 complexes [2]. - However, in patients with prior exposure to heparin, HIT can occur much sooner, even within **24 hours**, due to pre-existing antibodies.
Question 518: Which of the following statements about oral iron preparations is correct?
- A. Most commonly used preparation is ferrous gluconate
- B. Ferrous fumarate is most efficient
- C. Ferric preparations are more effective
- D. Different preparations have different bioavailability (Correct Answer)
Explanation: ***Different preparations have different bioavailability*** - The **bioavailability** of oral iron preparations varies depending on the specific salt used, its formulation, and the presence of absorption enhancers or inhibitors. - This difference in absorption impacts the required dose and efficacy in treating **iron deficiency anemia**. *Most commonly used preparation is ferrous gluconate* - **Ferrous sulfate** is the most commonly prescribed and cost-effective oral iron preparation due to its high iron content and good bioavailability. - While ferrous gluconate is used, its iron content is lower than ferrous sulfate, making it less frequently the primary choice. *Ferrous fumarate is most efficient* - While **ferrous fumarate** has a high elemental iron content, its efficiency doesn't necessarily surpass that of ferrous sulfate or other preparations when considering factors like bioavailability and side effect profile. - **Ferrous sulfate** is often considered efficient due to its balance of elemental iron content, bioavailability, and cost-effectiveness. *Ferric preparations are more effective* - **Ferrous (Fe2+)** iron is generally better absorbed than **ferric (Fe3+)** iron, as ferric iron needs to be reduced to its ferrous form before absorption. - Unless specifically formulated for enhanced absorption (e.g., ferric maltol), ferric preparations are typically *less* effective for initial iron repletion.
Question 519: What is the mechanism of action of ticagrelor?
- A. Reversible inhibition of ADP action (Correct Answer)
- B. Irreversible inhibition of ADP action
- C. Reversible inhibition of GPIIb/IIIa
- D. Irreversible inhibition of GPIIb/IIIa
Explanation: ***Reversible inhibition of ADP action*** - **Ticagrelor** is a **P2Y12 receptor antagonist** that works by preventing ADP from binding to its receptor on platelets [2]. - This binding is **reversible**, meaning ticagrelor can dissociate from the receptor, allowing for some recovery of platelet function over time [2]. *Irreversible inhibition of ADP action* - **Clopidogrel** and **prasugrel** are examples of **irreversible P2Y12 inhibitors**, forming a permanent bond with the receptor [2]. - Irreversible inhibition leads to a longer duration of platelet inhibition, as new platelets must be generated for function to return [2]. *Reversible inhibition of GPIIb/IIIa* - **GPIIb/IIIa inhibitors** like **eptifibatide** and **tirofiban** block the final common pathway of platelet aggregation by preventing fibrinogen binding [1]. - While their action is reversible, they target a *different* mechanism than ticagrelor. *Irreversible inhibition of GPIIb/IIIa* - **Abciximab** is a GPIIb/IIIa inhibitor that binds **irreversibly** (or with very slow dissociation) to the receptor [1]. - Unlike reversible GPIIb/IIIa inhibitors, abciximab is a monoclonal antibody with a prolonged antiplatelet effect [1]. - This is still an incorrect answer as ticagrelor targets the P2Y12 receptor, not GPIIb/IIIa.
Physiology
1 questionsRebound increase in gastric acid secretion after stopping proton pump inhibitor therapy is due to?
NEET-PG 2015 - Physiology NEET-PG Practice Questions and MCQs
Question 511: Rebound increase in gastric acid secretion after stopping proton pump inhibitor therapy is due to?
- A. Parietal cell hyperplasia
- B. Increased histamine release
- C. Hypergastrinemia (Correct Answer)
- D. Hypersensitivity of Ach receptors
Explanation: ***Hypergastrinemia*** - Proton pump inhibitors (PPIs) create a state of **hypochlorhydria** (reduced stomach acid), which in turn stimulates the **G cells** in the stomach to produce more **gastrin**. - This elevated gastrin level leads to a compensatory increase in the number and activity of **parietal cells**, causing a rebound hypersecretion of acid when PPI therapy is discontinued. *Parietal cell hyperplasia* - While parietal cell hyperplasia can occur, it is a consequence of chronic **hypergastrinemia**, not the primary driver of rebound acid secretion. - The direct effect of increased gastrin stimulating existing parietal cells is more immediate and significant for the rebound phenomenon. *Increased histamine release* - Elevated histamine release from **enterochromaffin-like (ECL) cells** is a downstream effect of hypergastrinemia, as gastrin stimulates ECL cells. - While increased histamine contributes to acid secretion, the root cause for its increase in this context is the **hypergastrinemia** induced by PPIs. *Hypersensitivity of Ach receptors* - **Acetylcholine (Ach) receptors** on parietal cells are involved in direct neural stimulation of acid secretion. - There is no evidence that stopping PPIs causes an increased sensitivity of these receptors, or that this is the primary mechanism of rebound acid secretion.